Drug Scandal Shocks France - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Drug Scandal Shocks France
Scandals regarding diabetes treatment Mediator frequently dominate French press headlines. Mediator was only withdrawn from the French market in November 2009, despite reports dating back as far as the 1990s linking similar products to valvular heart disease and pulmonary arterial hypertension. The end result is a great dissatisfaction among the French public with the French medicines regulator and the pharmaceutical industry, prompting a thorough reform of the country's pharmacovigilance system.

Pharmaceutical Technology Europe
Volume 23, Issue 3


1. EMA, "Questions and answers on the withdrawal of medicines containing benfluorex" (2010). http://www.ema.europa.eu

2. Inpharm, "Servier's Mediator provokes French drug safety controversy" (2010). http://www.inpharm.com

3. D.J. Heal, J. Gosden and S.L. Smith, Br. J Clin. Pharmacol., 68(6), 861–874 (2009).

4. FDA, "Questions and Answers about Withdrawal of Fenfluramine (Pondimin) and Dexfenfluramine (Redux)" (1997). http://www.fda.gov

5. Libération, "Un mal rare pour quelques kilos de trop" (2000). http://www.liberation.fr

6. J.R. Ribera et al., Rev. Esp. Cardiol., 56(2), 215–6 (2003).

7. Le Figaro, "Mediator: l'Assurance maladie mettait en garde dès 1998" (2011). http://www.lefigaro.fr

8. Le Post, "Mediator: Jacques Servier a-t-il financé Nicolas Sarkozy et l'UMP?" (2010). http://www.lepost.fr

9. Le Monde, "Mediator: Xavier Bertrand annonce une réforme de la pharmaco-vigilance" (2011). http://www.lemonde.fr


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology Europe,
Click here